Sweating does not appear in clinical trial data or post-marketing surveillance reports as a direct consequence of semaglutide therapy
Use plain, unsweetened yogurt and sweeten naturally
Tirzepatide (brand Mounjaro), a dual GIP/GLP-1 agonist, was approved for diabetes (2022) and for weight loss as Zepbound (2023)
Weight Lossbut Less Movement Researchers looked at people with obesity who lost weight while taking a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists
Were excited to help consumers access one of the most anticipated weight-loss treatments on the market, commented Wendy Barnes, president and CEO of GoodRx
If youre using GLP-1s for diabetes management: HbA1c and fasting glucose are primary markers Kidney function is monitored more closely, especially if you take metformin or insulin Lipids help track cardiovascular risk If youre using GLP-1s primarily for weight loss: Baseline metabolic labs still matter Liver enzymes and kidney function help track safety Blood sugar markers may be checked less frequently if you dont have diabetes In both cases, testing is most useful because it informs decisions, and empowers the user to own their health
